Premium
Comparison of methods of evaluating nephrotoxicity of cis‐platinum
Author(s) -
Jones Brian R,
Bhalla Ravi B,
Mladek Jiri,
Kaleya Ronald N,
Gralla Richard J,
Alcock Nancy W,
Schwartz Morton K,
Young Charles W,
Reidenberg Marcus M
Publication year - 1980
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1980.79
Subject(s) - nephrotoxicity , excretion , urology , medicine , renal physiology , urinary system , platinum , kidney , endocrinology , pharmacology , chemistry , biochemistry , catalysis
The urinary excretion of leucine aminopeptidase (LAP), N ‐acetyl‐β‐glucosaminidase (NAG), and β 2 ‐microglobulin was measured in 12 cancer patients receiving cis‐platinum to evaluate the sensitivity of these indices for renal tubular damage. NAG and LAP excretion rose markedly in all patients, and β 2 ‐microglobutin rose in 11. Seven of the 9 patients who had received cis‐platinum 6 wk before the study had prestudy dose elevations of one or more of these indices. We conclude that these urinary proteins are sensitive indicators of proximal renal tubular injury and may provide greater sensitivity for comparison of the nephrotoxic potential of future platinum analogs or for assessing the efficacy of regimens designed to protect the kidney from platinum nephrotoxicity than other measurements. The persistence of high excretion values for these indices 6 wk after a dose demonstrates the persistent renal injury by cis‐platinum. Clinical Pharmacology and Therapeutics (1980) 27, 557–562; doi: 10.1038/clpt.1980.79